Are add-on agents to statin therapy necessary in hypercholesterolemia?

References

• Ford ES, Li C, Pearson WS, Zhao G, Mokdad AH. Trends in hypercholesterolemia, treatment and control among United States adults. Int. J. Cardiol. 140(2), 226–235 (2010).
   Google Scholar
• World Health Organization. Global Health Observatory. Raised cholesterol: situation and trends. (2008). www.who.int
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3), 351–364 (1984).
   Google Scholar
• Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics‐‐2013 update: a report from the American Heart Association. Circulation 127(1), e6–e245 (2013).
   Google Scholar
• European Heart Network: European Cardiovascular Disease Statistics 2012. www.ehnheart.org
   Google Scholar
• NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
   Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364), 1149–1158 (2003).
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7–22 (2002).
   Google Scholar
• Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46(10), 1855–1862 (2005).
   Google Scholar
• Gotto AM Jr. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Trans. Am. Clin. Climatol. Assoc. 122, 256–289 (2011).
   Google Scholar
• European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL et al. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32(14), 1769–1818 (2011).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227–239 (2004).
   Google Scholar
• Jellinger PS, Smith DA, Mehta AE et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pract. 18(Suppl. 1), 1–78 (2012).
   Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 63(25 Pt B), 2889–2934 (2014).
   Google Scholar
• Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasoundderived coronary atheroma burden. Circulation 117(19), 2458–2466 (2008).
   Google Scholar
• Herd JA. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am. J. Med. 104(6A), 42S–49S (1998).
   Google Scholar
• Blankenhorn DH, Azen SP, Kramsch DM et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. 119(10), 969–976 (1993).
   Google Scholar
• World Health Organization. Prevention of Cardiovascular Disease: Pocket Guidelines for Assessment and Management of Cardiovascular Risk. (2007). www.who.int/cardiovascular_diseases
   Google Scholar
• Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).
   Google Scholar
• Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of statins in primary Prevention: an Intervention Trial Evaluating Rosuvastatin) study. J. Am. Coll. Cardiol. 53(11), 931–935 (2009).
   Google Scholar
• European Atherosclerosis Society. New guidelines in USA: how do they compare with the EAS/ESC guidelines for the management of dyslipidaemia? (2013). www.eas-society.org
   Google Scholar
• Yan AT, Yan RT, Tan M et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am. J. Med. 119(8), 676–683 (2006).
   Google Scholar
• Robinson JG, Ballantyne CM, Hsueh W et al. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J. Clin. Lipidol. 5(6), 474–482 (2011).
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160(4), 459–467 (2000).
   Google Scholar
• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929–940 (2009).
   Google Scholar
• Kotseva K, Wood D, De Backer G et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur. J. Cardiovasc. Prev. Rehabil. 17(5), 530–540 (2010).
   Google Scholar
• Bozentowicz-Wikarek M, Kocelak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis – guidelines vs. reality. Pharmacol. Rep. 64(2), 377–385 (2012).
   Google Scholar
• Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J. Am. Heart Assoc. 1(6), e001800 (2012).
   Google Scholar
• Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).
   Google Scholar
• Armitage J, Bowman L, Wallendszus K et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376(9753), 1658–1669 (2010).
   Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet 370(9601), 1781–1790 (2007).
   Google Scholar
• Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. 40(3), 567–572 (2002).
   Google Scholar
• Sathasivam S, Lecky B. Statin induced myopathy. BMJ 337, a2286 (2008).
   Google Scholar
• Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 131(11), 1427–1434 (2013).
   Google Scholar
• Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. Embo. J. 25(7), 1419–1425 (2006).
   Google Scholar
• Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32(Suppl. 2), S237–S245 (2009).
   Google Scholar
• Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89(1), 147–191 (2009).
   Google Scholar
• Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled Type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31(8), 1479–1484 (2008).
   Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with Type 2 diabetes mellitus and inadequate glycemic control receiving insulinbased therapy. Arch. Intern. Med. 168(14), 1531–1540 (2008).
   Google Scholar
• Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with Type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168(18), 1975–1983 (2008).
   Google Scholar
• Welchol®, prescribing information. Daiichi Sankyo, Inc. NJ, USA (2014).
   Google Scholar
• Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies. Stargrove MB, Treasure J, Mckee DL (Eds). Mosby Elsevier, MO, USA (2008).
   Google Scholar
• Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South. Med. J. 99(3), 257–273 (2006).
   Google Scholar
• Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am. J. Cardiol. 97(8), 1198–1205 (2006).
   Google Scholar
• Sprecher DL, Abrams J, Allen JW et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann. Intern. Med. 120(7), 537–543 (1994).
   Google Scholar
• Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N. Engl. J. Med. 332(17), 1125–1131 (1995).
   Google Scholar
• Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279(18), 1458–1462 (1998).
   Google Scholar
• Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr. Med. Res. Opin. 24(4), 995–1009 (2008).
   Google Scholar
• Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 121(6), 416–422 (1994).
   Google Scholar
• Handelsman Y, Goldberg RB, Garvey WT et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr. Pract. 16(4), 617–628 (2010).
   Google Scholar
• Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258(2), 94–114 (2005).
   Google Scholar
• Clofibrate and niacin in coronary heart disease. JAMA 231(4), 360–381 (1975).
   Google Scholar
• Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323(19), 1289–1298 (1990).
   Google Scholar
• Kwiterovich PO. A review of lipid-modifying drugs used alone and in combination. Johns Hopkins Advanced Studies in Medicine 5(9), 475–491 (2005).
   Google Scholar
• Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am. J. Cardiol. 73(14), 25D–29D (1994).
   Google Scholar
• Davignon J, Roederer G, Montigny M et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am. J. Cardiol. 73(5), 339–345 (1994).
   Google Scholar
• Vacek JL, Dittmeier G, Chiarelli T, White J, Bell HH. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for Type II hyperlipoproteinemia. Am. J. Cardiol. 76(3), 182–184 (1995).
   Google Scholar
• Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 16(3), 419–423 (1996).
   Google Scholar
• Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am. J. Cardiol. 91(6), 667–672 (2003).
   Google Scholar
• Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol. 89(6), 672–678 (2002).
   Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583–1592 (2001).
   Google Scholar
• Van JT, Pan J, Wasty T, Chan E, Wu X, Charles MA. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am. J. Cardiol. 89(11), 1306–1308 (2002).
   Google Scholar
• Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am. J. Cardiol. 91(11), 1304–1310 (2003).
   Google Scholar
• Bays HE, Ballantyne C. What’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr. Opin. Lipidol. 20(6), 467–476 (2009).
   Google Scholar
• Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med. 162(14), 1568–1576 (2002).
   Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart. J. 32(11), 1345–1361 (2011).
   Google Scholar
• Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc. Health Risk Manag. 6, 525–539 (2010).
   Google Scholar
• Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am. J. Cardiol. 96(9A), K3–K13; discussion K34–K35 (2005).
   Google Scholar
• Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol. 99(6A), C3–C18 (2007).
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563–1574 (2010).
   Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084–1091 (2002).
   Google Scholar
• Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125–2134 (2002).
   Google Scholar
• Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert. Rev. Cardiovasc. Ther. 6(4), 447–470 (2008).
   Google Scholar
• Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 8, 415–427 (2012).
   Google Scholar
• Gillett RC Jr, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am. Fam. Physician 83(6), 711–716 (2011).
   Google Scholar
• Jacobson TA, Ito MK, Maki KC et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary. J. Clin. Lipidol. 8(5), 473–488 (2014).
   Google Scholar
• Goff DC Jr, Lloyd-Jones DM, Bennett G et al. 2013 ACC/ AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2), S49–S73 (2013).
   Google Scholar
• Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123(20), 2292–2333 (2011).
   Google Scholar
• Wierzbicki A. Homozygous familial hypercholesterolemia. Clin. Lipidol. 8(4), 407–409 (2013).
   Google Scholar
• Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vascul. Pharmacol. 62(2), 103–111 (2014).
   Google Scholar
• Pandor A, Ara RM, Tumur I et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J. Intern. Med. 265(5), 568–580 (2009).
   Google Scholar
• Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in Type 2 diabetes mellitus with hypercholesterolemia. Endocr. J. 54(1), 53–58 (2007).
   Google Scholar